Recent Finacing
Recent Raise
EMERCell develops immunotherapies using a patented process to pre-activate and amplify allogeneic NK cells; its ATMP NK-001 targets CD20+ refractory lymphomas, with clinical trial and production scale-up plans.
Focus Areas
Recent Investors
Funding round
Investor